Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1988-3-24
|
pubmed:abstractText |
Since 1978, 187 patients (age range, 15 to 59, median 44 years) have received short-term chemotherapy as part of three sequential open studies (B-IX, X, Xb) or a randomized clinical trial (B-XI). An intended six cycles of Adriamycin (ADR) (doxorubicin; Adria Laboratories, Columbus, OH), cytarabine (ara-C), and thioguanine (TG) were administered with as short an intercycle time as possible. No further therapy was administered. Complete remission (CR) was achieved in 118 of 187 patients (63%). On univariate and multivariate analyses achievement of CR correlated adversely with a low serum albumin at presentation and an antecedent marrow disorder. Forty-five patients continue in first remission between 15 months and 8 1/2 years, no relapses being seen after 3 1/2 years (median follow-up, 3 1/2 years). The median duration of remission was 1 year. M3 morphology, a blast count less than 100 x 10(9)/L, and absence of hepatosplenomegaly correlated favorably with remission duration. There was no difference in duration of remission between patients receiving 3, 4, 5, or 6 cycles. The best results overall were achieved in patients under the age of 40, with 43% projected to remain free of disease at 5 years. Fifty patients remain alive between 17 months and 9 years, the predicted actuarial survival being 25% at 5 years.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0732-183X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
6
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
N
|
pubmed:pagination |
218-26
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:3422261-Actuarial Analysis,
pubmed-meshheading:3422261-Adolescent,
pubmed-meshheading:3422261-Adult,
pubmed-meshheading:3422261-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:3422261-Cytarabine,
pubmed-meshheading:3422261-Doxorubicin,
pubmed-meshheading:3422261-Drug Administration Schedule,
pubmed-meshheading:3422261-Female,
pubmed-meshheading:3422261-Humans,
pubmed-meshheading:3422261-Leukemia, Myeloid, Acute,
pubmed-meshheading:3422261-Male,
pubmed-meshheading:3422261-Middle Aged,
pubmed-meshheading:3422261-Remission Induction
|
pubmed:year |
1988
|
pubmed:articleTitle |
Short-term therapy for acute myelogenous leukemia.
|
pubmed:affiliation |
Department of Medical Oncology, St. Bartholomew's Hospital, London, England.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|